Deutsche Bank analyst Justin Bowers initiated coverage of West Pharmaceutical with a Hold rating and $250 price target. The analyst launched coverage of 10 life science tools companies that have "outsized exposure" to the biopharma end market. The stocks that outperform in 2023 "will provide downside protection or are idiosyncratic," Bowers tells investors in a research note. He recommends "captains of culture" Danaher (DHR) and Thermo Fisher Scientific (TMO) for more defensive posturing. Buy-rated rated Maravai Lifesciences (MRVI), Bio-Techne (TECH) and 10X Genomics (TXG) offer novel technology and have embedded optionality, Bowers tells investors in a research note. His Hold-rated names reflect wanting better entry points andconviction in consensus estimates.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on WST:
- West Announces First-Quarter 2023 Dividend and Participation in Upcoming Investor Conference
- West Pharmaceutical price target lowered to $315 from $350 at KeyBanc
- West Pharmaceutical initiated with a Neutral at UBS
- West Announces Third-Quarter 2022 Results, Updates Full-Year 2022 Guidance and Declares Fourth-Quarter 2022 Dividend